Intervention
Cadonilimab
ClinicalTrials.gov intervention label
Clinical trials
16 shownA Study of Ivonescimab in First-Line ES-SCLCNCT07245446 · 2025-10-29
RECRUITINGPhase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLCNCT06769971 · 2025-02-01
RECRUITINGAK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic TherapyNCT06494995 · 2024-07-03
RECRUITINGCadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast CancerNCT06367088 · 2024-05-01
RECRUITINGCryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary MetastasesNCT06265350 · 2024-02-02
RECRUITINGCadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) NegativeNCT06001151 · 2023-08-07
RECRUITINGTIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II StudyNCT05882370 · 2022-12-01
RECRUITINGPhase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaNCT07243951 · 2025-11-28
NOT_YET_RECRUITINGStudy of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast CancerNCT06202313 · 2024-02-10
NOT_YET_RECRUITINGStudy of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain MetastasesNCT05812534 · 2023-12-01
UNKNOWNCadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLCNCT06424821 · 2023-07-04
UNKNOWNStereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid TumorsNCT05915481 · 2023-06-21
UNKNOWNCadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung CancerNCT05784974 · 2023-05-01
NOT_YET_RECRUITINGCadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)NCT05816499 · 2023-02-16
UNKNOWNCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal CancerNCT05426005 · 2023-02-07
ACTIVE_NOT_RECRUITINGCadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLCNCT05901584 · 2023-01-01
UNKNOWNCommon conditions
Cadonilimab2Hepatocellular Carcinoma2Advanced Solid Tumor1Bevacizumab1Brain Metastases1Carcinoma, Non-Small-Cell Lung1Colorectal Cancer Stage IV1Combined Hepatocellular-cholangiocarcinoma1Cryoablation1Efficacy1Extensive-stage Small Cell Lung Cancer (ES-SCLC)1Head and Neck Squamous Cell Carcinoma1Immune Checkpoint Inhibitor1Immunotherapy1Liver Cancer Stage IV1Liver Neoplasms1Lung Cancer1Microsatellite Instability-high (MSI-H)1Mismatch Repair-deficient (dMMR)1Non Small Cell Lung Cancer1NSCLC1NSCLC Stage IIIB1NSCLC Stage IIIC1NSCLC Stage IV1Pulmonary Metastases1
Leading sponsors
Sun Yat-sen University2Akeso1Fei Gao1Fudan University1Peking University Third Hospital1Qian Chu1Second Affiliated Hospital of Nanchang University1Second Affiliated Hospital of Zunyi Medical University1Shanghai Chest Hospital1Shanghai Pulmonary Hospital, Shanghai, China1Shanghai Zhongshan Hospital1Shengjing Hospital1Sichuan University1The First Hospital of Jilin University1Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
Trial status mix
RECRUITING7
UNKNOWN5
NOT_YET_RECRUITING3
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE215
PHASE13
NA1
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.